Prof Philipp Jost, along with other leading experts in the field, authored an invited commemorative review in Cell by Cell Press — titled “𝘾𝙚𝙡𝙡 𝘿𝙚𝙖𝙩𝙝 𝙞𝙣 𝘾𝙖𝙣𝙘𝙚𝙧”. The review highlights how the expanding landscape of regulated cell death pathways is reshaping our understanding of cancer biology and unlocking new therapeutic opportunities.
🔗 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲: here
We are excited to share that our Founder, 𝗣𝗿𝗼𝗳. 𝗗𝗿. Philipp Jost, will be presenting at the 𝗔𝗔𝗖𝗥 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟲 in San Diego this
We’re proud to share that 𝗣𝗿𝗼𝗳. 𝗗𝗿. Philipp Jost , Scientific Founder of Cycuria Therapeutics , is featured in Drug Target Review discussing innovative strategies
Our CEO & Co-Founder, Nisit Khandelwal, joined host Jim Cornall on the 𝗕𝗮𝘀𝗲-𝘁𝗼-𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 to discuss Cycuria Therapeutics’ approach to treating some of the
Editor’s summary Relapse of acute myeloid leukemia (AML) is driven by populations of leukemic stem or progenitor cells (LSCs), which are resistant to chemotherapy. Here,
At Cycuria, we are dedicated to developing novel cytokine-based therapies to dramatically improve outcomes for patients living with cancer, offering hope where traditional treatments have fallen short.